Throughout the patient pathway, consideration should be given to patient eligibility and suitability for available clinical trials and discussed with individual patients as appropriate.

Patients with mixed SCLC/NSCLC pathology or those for concurrent chemoradiotherapy but with insufficient tissue sample for clear pathology, may be considered for carboplatin and etoposide.

Author Nicola Steele (on behalf of SACT subgroup) Reviewer John Maclay
Date of creation/update 20/09/2023 Version number 1.0
Review Date 20/09/2026 Contact nss.scottishcancernetwork@nhs.scot
The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.